
Zetagen to Share Phase 2 Data on Bone-Metastatic Breast Cancer at SABCS 2025
Zetagen Therapeutics Announces Presentation of Promising Phase 2a Data Demonstrating Complete Responses in Metastatic Breast Cancer Bone Lesions at 2025 SABCS Zetagen Therapeutics, a privately held clinical-stage biopharmaceutical company developing…












